Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RNAi-mediated silencing of hepatic <i>Alas1</i> effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice

12 May 2014

Abstract excerpt

The acute hepatic porphyrias are inherited disorders of heme biosynthesis characterized by life-threatening acute neurovisceral attacks. Factors that induce the expression of hepatic 5-aminolevulinic acid synthase 1 (ALAS1) result in the accumulation of the neurotoxic porphyrin precursors 5-aminolevulinic acid (ALA) and porphobilinogen (PBG), which recent studies indicate are primarily responsible for the acute...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Heme Oxygenase-1 and Carbon Monoxide
Share to Neonatal Health and Biochemistry
Share to Porphyrin Metabolism and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24821812
DOI: 10.1073/pnas.1406228111

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RNAi-mediated silencing of hepatic <i>Alas1</i> effectively prevents and treats the induced acute attacks in acute intermittent porphyria micePMID 24821812Read ↗

Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent PorphyriaSemantic proximity Read ↗

Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent PorphyriaSemantic proximity Read ↗

Acute hepatic and erythropoietic porphyrias: from ALA synthases 1 and 2 to new molecular bases and treatments.Semantic proximity Read ↗

Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension studySemantic proximity Read ↗

Acute Intermittent PorphyriaSemantic proximity Read ↗

Diagnosis and therapy of acute intermittent porphyria.Semantic proximity Read ↗

5-Aminolevulinate dehydratase porphyria: Update on hepatic 5-aminolevulinic acid synthase induction and long-term response to hemin.Semantic proximity Read ↗

Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators.Semantic proximity Read ↗

Efficacy and safety of givosiran in Japanese patients with acute hepatic porphyria: Clinical findings from an expanded access studySemantic proximity Read ↗

Molecular basis of acute intermittent porphyria.Semantic proximity Read ↗

Host porphobilinogen deaminase deficiency confers malaria resistance in <i>Plasmodium chabaudi</i> but not in <i>Plasmodium berghei</i> or <i>Plasmodium falciparum</i> during intraerythrocytic growthSemantic proximity Read ↗

mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacksSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.